Thrombospondin-1 and -2 in node-negative breast cancer: correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis
- PMID: 11150912
- DOI: 10.1159/000055300
Thrombospondin-1 and -2 in node-negative breast cancer: correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis
Abstract
Objective: Thrombospondins (TSP(s)) are a multigene family of five secreted glycoproteins involved in the regulation of cell proliferation, adhesion and migration. Two members of the TSP family, namely TSP-1 and TSP-2, are also naturally occurring inhibitors of angiogenesis. The aim of the present study was to determine the prognostic significance of the determination of TSP-1 and -2 and their correlation with the angiogenic peptides vascular endothelial growth factor (VEGF) and thymidine phosphorylase (TP), as well as with other biological and clinicopathological features investigated.
Methods: We evaluated a series of 168 women with node-negative breast cancer with a median follow-up period of 66 months, not treated with adjuvant therapy. The cytosolic levels of TSP-1 and -2 were determined in the primary tumour by a commercially available immunometric assay.
Results: We found that 166 tested tumours had measurable levels of TSP-1 and -2 protein (median value 5.978, range 0.579-31.410 ng/mg of protein). On the basis of Spearman's rank correlation coefficient, a weak inverse association of TSP-1 and -2 with tumour size and cathepsin D was found. Moreover, principal component analysis on ranks evidenced a poor association between TSP-1 and -2, VEGF and TP. The results of the clinical outcome were analysed by both univariate and multivariate [for relapse-free survival (RFS) only]) Cox regression models. TSP-1 and -2 were not significant prognostic factors in univariate analysis for either RFS (p = 0.427) or overall survival (p = 0.069). To investigate the 'angiogenic balance hypothesis', bivariate analyses were performed to investigate the interactions of TSP-1 and -2 with VEGF, TP or p53, but none were included in the selected models. Finally, in multivariate analysis for RFS a baseline model, previously defined in a larger case series and inclusive of VEGF, TP and their interaction was adopted. It was highly significant (p = 0.002, Harrell c statistic value of 0.703); but when TSP-1 and -2 were added, their contribution was negligible (p = 0.731, Harrell c statistic value of 0.705).
Conclusions: The results of this study suggest that TSP-1 and -2 do not provide additional prognostic contribution to the joint effects of VEGF and TP. In the series of node-negative breast cancer patients investigated, determination of the angiogenic peptides VEGF and TP gave significant prognostic information. On the contrary, TSP-1 and -2, potential naturally occurring negative regulators of angiogenesis, lacked prognostic value.
Similar articles
-
Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.Cancer J Sci Am. 1999 Mar-Apr;5(2):101-11. Cancer J Sci Am. 1999. PMID: 10198732 Clinical Trial.
-
Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma.J Natl Cancer Inst. 1997 Jan 15;89(2):139-47. doi: 10.1093/jnci/89.2.139. J Natl Cancer Inst. 1997. PMID: 8998183
-
Co-determination of the angiogenic factors thymidine phosphorylase and vascular endothelial growth factor in node-negative breast cancer: prognostic implications.Angiogenesis. 1997;1(1):71-83. doi: 10.1023/A:1018305132489. Angiogenesis. 1997. PMID: 14517395
-
Clinical significance of angiogenic factors in breast cancer.Breast Cancer Res Treat. 1998;52(1-3):159-73. doi: 10.1023/a:1006175504673. Breast Cancer Res Treat. 1998. PMID: 10066080 Review.
-
Prognostic value of vascular endothelial growth factor in breast cancer.Oncologist. 2000;5 Suppl 1:37-44. doi: 10.1634/theoncologist.5-suppl_1-37. Oncologist. 2000. PMID: 10804090 Review.
Cited by
-
Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon?EPMA J. 2013 Feb 19;4(1):6. doi: 10.1186/1878-5085-4-6. EPMA J. 2013. PMID: 23418957 Free PMC article.
-
sFRP-1 binds via its netrin-related motif to the N-module of thrombospondin-1 and blocks thrombospondin-1 stimulation of MDA-MB-231 breast carcinoma cell adhesion and migration.Arch Biochem Biophys. 2011 May 15;509(2):147-56. doi: 10.1016/j.abb.2011.03.004. Epub 2011 Mar 21. Arch Biochem Biophys. 2011. PMID: 21402050 Free PMC article.
-
The association between vascular endothelial growth factor expression in invasive breast cancer and survival varies with intrinsic subtypes and use of adjuvant systemic therapy: results from the Nurses' Health Study.Breast Cancer Res Treat. 2011 Aug;129(1):175-84. doi: 10.1007/s10549-011-1432-3. Epub 2011 Mar 9. Breast Cancer Res Treat. 2011. PMID: 21390493 Free PMC article.
-
Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth.J Cell Mol Med. 2002 Jan-Mar;6(1):1-12. doi: 10.1111/j.1582-4934.2002.tb00307.x. J Cell Mol Med. 2002. PMID: 12003665 Free PMC article. Review.
-
Human expression patterns: qualitative and quantitative analysis of thrombospondin-1 under physiological and pathological conditions.J Cell Mol Med. 2018 Apr;22(4):2086-2097. doi: 10.1111/jcmm.13565. Epub 2018 Feb 14. J Cell Mol Med. 2018. PMID: 29441713 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous